Orbcel-C
Hepatitis, Autoimmune
University of BirminghamCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Hepatitis, Autoimmune cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Azathioprine Xiaoli Fan | Phase 4 | BB |
URSODEOXYCHOLIC ACID West China Hospital | Phase 4 | BB |
CYCLOSPORIN A West China Hospital | Phase 4 | B |
Jkb-122 TaiwanJ Pharmaceuticals Co., Ltd | Phase 2 | CCC |
Siplizumab Elizabeth C. Verna | Phase 1 | C |
METRONIDAZOLE Cliniques universitaires Saint-Luc- Université Catholique de Louvain | N/A | D |
Budesonide Mayo Clinic | N/A | D |
Same molecule, other indications
Orbcel-C is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →